Impact of once-weekly subcutaneous semaglutide 2.4 mg on metabolic syndrome in the 2-year, randomised controlled STEP 5 trial

被引：0
|
作者：
Dimitriadis, Georgios K. [1 ]
Batterham, Rachel [2 ]
Bhatta, Meena [3 ]
Holst-Hansen, Thomas [3 ]
Kandler, Kristian [3 ]
Rigas, Georgia [4 ]
Garvey, W. Timothy [5 ]
机构：
[1] Kings Coll London, London, England
[2] UCL, Div Med, Obes Res Ctr, London, England
[3] Novo Nordisk AS, Soborg, Denmark
[4] St George Private Hosp, Dept Bariatr Metab Surg, Kogarah, NSW, Australia
[5] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL USA
来源：
OBESITY SURGERY | 2023年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
引用
收藏
页码：S119 / S119
页数：1
相关论文
共 50 条
  • [41] Once-Weekly Risedronate in Men With Osteoporosis: Results of a 2-Year, Placebo-Controlled, Double-Blind, Multicenter Study
    Boonen, Steven
    Orwoll, Eric S.
    Wenderoth, Dietrich
    Stoner, Karen J.
    Eusebio, Rachelle
    Delmas, Pierre D.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2009, 24 (04) : 719 - 725
  • [42] Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta-analysis including the 2-year STEP 5 trial
    Qin, Wenhui
    Yang, Jun
    Deng, Chao
    Ruan, Qinjuan
    Duan, Kai
    DIABETES OBESITY & METABOLISM, 2024, 26 (03): : 911 - 923
  • [43] Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial
    Kaku, Kohei
    Yamada, Yuichiro
    Watada, Hirotaka
    Abiko, Atsuko
    Nishida, Tomoyuki
    Zacho, Jeppe
    Kiyosue, Arihiro
    DIABETES OBESITY & METABOLISM, 2018, 20 (05): : 1202 - 1212
  • [44] Once-weekly semaglutide in people with HIV-associated lipohypertrophy: a randomised, double-blind, placebo-controlled phase 2b single-centre clinical trial
    Eckard, Allison Ross
    Wu, Qian
    Sattar, Abdus
    Ansari-Gilani, Kianoush
    Labbato, Danielle
    Foster, Theresa
    Fletcher, Aaron A.
    Adekunle, Ruth
    McComsey, Grace A.
    LANCET DIABETES & ENDOCRINOLOGY, 2024, 12 (08): : 523 - 534
  • [45] Efficacy and safety of once weekly semaglutide 2<middle dot>4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7) : a double-blind, multicentre, randomised controlled trial
    Mu, Yiming
    Bao, Xiaolei
    Eliaschewitz, Freddy G.
    Hansen, Morten Rix
    Kim, Bom Taeck
    Koroleva, Anna
    Ma, Ronald C. W.
    Yang, Tao
    Zu, Ning
    Liu, Ming
    LANCET DIABETES & ENDOCRINOLOGY, 2024, 12 (03): : 184 - 195
  • [46] Acupuncture for irritable bowel syndrome: 2-year follow-up of a randomised controlled trial
    MacPherson, Hugh
    Tilbrook, Helen
    Agbedjro, Deborah
    Buckley, Hannah
    Hewitt, Catherine
    Frost, Chris
    ACUPUNCTURE IN MEDICINE, 2017, 35 (01) : 17 - 23
  • [47] Effect of once-weekly semaglutide on the counterregulatory response to hypoglycaemia in people with type 2 diabetes: A randomized, placebo-controlled, double-blind, crossover trial
    Korsatko, Stefan
    Jensen, Lene
    Brunner, Martina
    Sach-Friedl, Stefanie
    Tarp, Maja D.
    Holst, Anders G.
    Heller, Simon R.
    Pieber, Thomas R.
    DIABETES OBESITY & METABOLISM, 2018, 20 (11): : 2565 - 2573
  • [48] Efficacy and Safety of Once-Weekly Somapacitan in Childhood Growth Hormone Deficiency: Results of a Randomised Open-Label, Controlled Phase 2 Trial
    Savendal, Lars
    Rasmussen, Michael
    Horikawa, Reiko
    Khadilkar, Vaman
    Battelino, Tadej
    Saenger, Paul
    HORMONE RESEARCH IN PAEDIATRICS, 2018, 90 : 58 - 58
  • [49] Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial
    Zinman, Bernard
    Bhosekar, Vaishali
    Busch, Robert
    Holst, Ingrid
    Ludvik, Bernhard
    Thielke, Desiree
    Thrasher, James
    Woo, Vincent
    Philis-Tsimikas, Athena
    LANCET DIABETES & ENDOCRINOLOGY, 2019, 7 (05): : 356 - 367
  • [50] Real-world impact of once-weekly subcutaneous semaglutide after 2 years of follow-up: Results from a nationwide observational study in people with type 2 diabetes
    Vilsboll, Tina
    Lindahl, Caroline O.
    Nielsen, Nick F.
    Tikkanen, Christian K.
    DIABETES OBESITY & METABOLISM, 2023, 25 (06): : 1740 - 1749
12345